148 related articles for article (PubMed ID: 8061431)
21. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience.
Gehl HB; Urhahn R; Bohndorf K; Klever P; Hauptmann S; Lodemann KP; Matern S; Schumpelick V; Günther RW
Radiology; 1993 Mar; 186(3):795-8. PubMed ID: 8430190
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of the normal pancreas: comparison of manganese-DPDP and gadolinium chelate.
Kettritz U; Warshauer DM; Brown ED; Schlund JF; Eisenberg LB; Semelka RC
Eur Radiol; 1996; 6(1):14-8. PubMed ID: 8797944
[TBL] [Abstract][Full Text] [Related]
23. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
24. A segmental hyperintensity area in the liver shown by delayed MR images with Mn-DPDP.
Suto Y; Weinreb JC; Rofski NM
J Comput Assist Tomogr; 1996; 20(4):647-9. PubMed ID: 8708073
[TBL] [Abstract][Full Text] [Related]
25. MRI contrast media for the liver. Efficacy in conditions of acute biliary obstruction.
Leander P; Golman K; Klaveness J; Holtz E; Olsson M; Leunbach I
Invest Radiol; 1990 Oct; 25(10):1130-4. PubMed ID: 2127772
[TBL] [Abstract][Full Text] [Related]
26. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images.
Vogl TJ; Hamm B; Schnell B; McMahon C; Branding G; Lissner J; Wolf KJ
J Magn Reson Imaging; 1993; 3(1):51-8. PubMed ID: 8381314
[TBL] [Abstract][Full Text] [Related]
27. MR imaging of pancreatic lesions. Comparison of manganese-DPDP and gadolinium chelate.
Diehl SJ; Lehmann KJ; Gaa J; McGill S; Hoffmann V; Georgi M
Invest Radiol; 1999 Sep; 34(9):589-95. PubMed ID: 10485075
[TBL] [Abstract][Full Text] [Related]
28. CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model.
Leander P; Månsson S; Ege T; Besjakov J
Acta Radiol; 1996 May; 37(3 Pt 1):242-9. PubMed ID: 8845249
[TBL] [Abstract][Full Text] [Related]
29. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
30. Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients.
Aicher KP; Laniado M; Kopp AF; Grönewäller E; Duda SH; Claussen CD
J Magn Reson Imaging; 1993; 3(5):731-7. PubMed ID: 8400558
[TBL] [Abstract][Full Text] [Related]
31. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
[TBL] [Abstract][Full Text] [Related]
32. [Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].
Vogl TJ; Hammerstingl R; Schnell B; Eibl-Eibesfeldt B; Peqios W; Lissner J
Bildgebung; 1992 Dec; 59(4):195-9. PubMed ID: 1292771
[TBL] [Abstract][Full Text] [Related]
33. Gd-BOPTA/Dimeg: experimental disease imaging.
Cavagna F; Daprà M; Maggioni F; de Haën C; Felder E
Magn Reson Med; 1991 Dec; 22(2):329-33; discussion 343-6. PubMed ID: 1812366
[TBL] [Abstract][Full Text] [Related]
34. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals.
de Haën C; La Ferla R; Maggioni F
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S169-79. PubMed ID: 10608413
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging.
Rofsky NM; Weinreb JC; Bernardino ME; Young SW; Lee JK; Noz ME
Radiology; 1993 Jul; 188(1):53-9. PubMed ID: 8390072
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model.
Marzola P; Maggioni F; Vicinanza E; Daprà M; Cavagna FM
J Magn Reson Imaging; 1997; 7(1):147-52. PubMed ID: 9039606
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of action of liver contrast agents: impact for clinical use.
Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
[TBL] [Abstract][Full Text] [Related]
39. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.
del Frate C; Bazzocchi M; Mortele KJ; Zuiani C; Londero V; Como G; Zanardi R; Ros PR
Radiology; 2002 Dec; 225(3):766-72. PubMed ID: 12461259
[TBL] [Abstract][Full Text] [Related]
40. MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP.
Coley BD; Mattrey RF; Baker KG; Peterson T; Burgan AR
J Magn Reson Imaging; 1995; 5(1):11-6. PubMed ID: 7696800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
